CVE:BCT - Briacell Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started C$0.15 +0.01 (+3.57 %) (As of 07/17/2018 11:26 AM ET)Previous CloseC$0.14Today's RangeC$0.14 - C$0.1552-Week RangeC$0.10 - C$0.20Volume8,500 shsAverage Volume199,405 shsMarket CapitalizationC$12.93 millionP/E RatioN/ADividend YieldN/ABeta0.8 Company ProfileInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing an approach to the management of cancer. The company is currently conducting a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT, in patients with advanced breast cancer. The trial is being conducted along with the co-development of BriaDX, a companion diagnostic test. It is also conducting a roll-over combination study of Bria-IMT with pembrolizumab or ipilimumab for patients previously treated with Bria-IMT in its ongoing Phase I/IIa clinical trial in advanced breast cancer. In addition, the company is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced stage breast cancer; and protein kinase C delta inhibitor, a novel therapeutic technology platform for the treatment of breast, pancreatic, and non-small cell lung cancer, as well as neuroendocrine tumors. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. Receive BCT News and Ratings via Email Sign-up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolCVE:BCT CUSIPN/A Webwww.briacell.com Phone+1-604-9211810 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-233.55% Return on Assets-137.92% Miscellaneous EmployeesN/A Outstanding Shares157,828,000Market CapC$12.93 Briacell Therapeutics (CVE:BCT) Frequently Asked Questions What is Briacell Therapeutics' stock symbol? Briacell Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BCT." What is the consensus analysts' recommendation for Briacell Therapeutics? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Briacell Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Briacell Therapeutics' key competitors? Some companies that are related to Briacell Therapeutics include Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP), Synthetic Biologics (SYN), DiaMedica Therapeutics (DMA), Antibe Therapeutics (ATE), Biopharmx (BPMX), Realm Therapeutics (RLM), Ceapro (CZO), Nuvo Pharmaceuticals (NRI), Concordia International (CXR), Netscientific (NSCI), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Kalytera Therapeutics (KALTF). Who are Briacell Therapeutics' key executives? Briacell Therapeutics' management team includes the folowing people: Dr. William V. Williams, CEO, Pres & DirectorDr. Charles Louis Wiseman M.D., FACP, Founder & DirectorMr. Gadi Levin, CFO & Corp. Sec. (Age 45)Ms. Farrah Dean MSc, MBA, Mang. of Corp. Devel.Dr. Markus Lacher Ph.D., Sr. Director of R&D Has Briacell Therapeutics been receiving favorable news coverage? Media headlines about BCT stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Briacell Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 44.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Briacell Therapeutics? Shares of BCT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Briacell Therapeutics' stock price today? One share of BCT stock can currently be purchased for approximately C$0.15. How big of a company is Briacell Therapeutics? Briacell Therapeutics has a market capitalization of C$12.93 million. How can I contact Briacell Therapeutics? Briacell Therapeutics' mailing address is Bellevue Centre, 235 15th St 3rd Floor, WEST VANCOUVER, BC V7T 2X1, Canada. The company can be reached via phone at +1-604-9211810. MarketBeat Community Rating for Briacell Therapeutics (CVE BCT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 16 (Vote Outperform)Underperform Votes: 13 (Vote Underperform)Total Votes: 29MarketBeat's community ratings are surveys of what our community members think about Briacell Therapeutics and other stocks. Vote "Outperform" if you believe BCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?